Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide [7]

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 8, 2006, Pages 1842-1845

  Palumbo, Antonio ^a   Rus, C ^a   Zeldis, J B ^b   Rodeghiero, F ^c   Boccadoro, M ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CELGENE CORPORATION   (United States)

^c SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ADULT; AGED; ARTERY THROMBOSIS; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INCIDENCE; LEG THROMBOSIS; LETTER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MYELOMA; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ASPIRIN; ENOXAPARIN; HUMANS; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; RECURRENCE; RISK; THALIDOMIDE; THROMBOEMBOLISM; TIME FACTORS;

EID: 33746593667     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02059.x     Document Type: Letter

References (21)

1. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22.
2. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet 1998; 351: 1077-80.
3. Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A, Whitfield D, Siegel E, Barlogie B, Fink L, Tricot G. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrin 2002; 13: 187-92.
4. Lee AYY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999; 25: 137-46.
5. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, Fassas A, Van Rhee F, Talamo G, Lee CK, Tricot G. Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival. Clin Lymph 2003; 4: 32-5.
6. Hussein MA. Lenalidomide: Patient management strategies. Semin Hematol 2005; 42: S22-5.
7. Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 1: 445-9.
8. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L, Tricot G. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614-5.
9. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, Iturria N, Kumar S, Lust JA, Kyle RA, Greipp PR, Witzig TE. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-9.
10. Palumbo A, Bertola A, Falco P, Rosato R, Cavallo F, Giaccone L, Bringhen S, Musto P, Pregno P, Caravita T, Ciccone G, Boccadoro M. Efficacy of low dose thalidomide and dexamethasone as first savage regimen in multiple myeloma. Hematol J 2004; 5: 318-24.
11. Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Nunzi M, Grasso M, Falco P, Cangialosi C, Boccadoro M. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer 2005; 104: 1428-33.
12. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 2003; 21: 4444-54.
13. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson CG, Turpie AG. Prevention of venous thromboembolism in medical patients with enoxaparin: A subgroup analysis of the MEDENOX study. Blood Coagul Fibrin 2003; 14: 341-6.
14. Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, Lee CK, Thertulien R, Talamo G, Thomas T, Van Rhee F, Fassas A, Fink L, Tricot G. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: Effects of prophylactic and therapeutical anticoagulation. Br J Haematol 2004; 126: 715-21.
15. Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, Karam MA, Faiman B, Jawde RA, Andresen S, Zeldis J, Hussein MA. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80: 1568-74.
16. Cavo M, Zamagni E, Cellini C, Tosi P, Cangini D, Cini M, Valdre L, Palareti G, Masini L, Tura S, Baccarani M. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002; 100: 2272-3.
17. Zonder JA, Durie BGM, McCoy J, Crowley J, Zeldis JB, Ghannam L, Barbogie B. High incidence of thrombotic events observed in patients receiving lenalidomide (L) + dexamethasone (D) (LD) as first-line therapy for multiple myeloma (MM) without aspirin (ASA) prophylaxis. Blood 2005; 106: 3455 (Abstract).
18. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, et al., Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006; 367: 825-31.
19. Palumbo A, Falco P, Musto P, Corradini P, Di Raimondo F, Rossi G, Giuliani N, Morabito F, Luraschi A, Falcone A, OmedèP, Gay F, Avonto I, Ambrosini MT, Bringhen S, Zeldis J, Knight R, Boccadoro M, Petrucci MT. Oral Revlimid R plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma. Blood 2005; 106: 785 (Abstract).
20. Dimopoulos MA, Spencer A, Attal M, Prince M, Harousseau JL, Dmoszynska A, Yu Z, Olesnyckyj M, Zeldis J, Knight R. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 study. Blood 2005; 106: 6 (Abstract).
21. Niesvizky R, Martinez-Banos DM, Gelbshtein UY, Cho HJ, Pearse RN, Zafar F, Pekle K, Furman R, Leonard JP, Coleman M. Prophylactic low-dose aspirin is effective as antithrombotic therapy in patients receiving combination thalidomide or lenalidomide. Blood 2005; 106: 3454 (Abstract).